Immunogen traded at $31.23 this Friday February 9th. Looking back, over the last four weeks, Immunogen lost 4.94 percent. Over the last 12 months, its price rose by 617.93 percent. Looking ahead, we forecast Immunogen to be priced at 30.57 by the end of this quarter and at 28.66 in one year, according to Trading Economics global macro models projections and analysts expectations.
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Its Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha (FRa)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. IMGN632 is an ADC comprised of a high-affinity antibody designed to target CD123 for patients with hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).